Q1 2018 EPS Estimates for Spark Therapeutics Inc Reduced by Wedbush (ONCE)
Spark Therapeutics Inc (NASDAQ:ONCE) – Analysts at Wedbush lowered their Q1 2018 earnings estimates for Spark Therapeutics in a note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($1.88) per share for the quarter, down from their prior forecast of ($1.80). Wedbush has a “Underperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.88) EPS, Q3 2018 earnings at ($1.90) EPS, Q4 2018 earnings at ($1.92) EPS, FY2018 earnings at ($7.57) EPS, FY2019 earnings at ($6.59) EPS, FY2020 earnings at ($5.62) EPS, FY2021 earnings at ($4.60) EPS and FY2022 earnings at ($3.22) EPS.
A number of other equities analysts also recently issued reports on ONCE. SunTrust Banks set a $101.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Credit Suisse Group assumed coverage on shares of Spark Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $61.00 price objective on the stock. Raymond James Financial set a $66.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Royal Bank of Canada dropped their price objective on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Finally, Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $74.45.
Spark Therapeutics (NASDAQ:ONCE) opened at $51.48 on Thursday. The stock has a market cap of $1,899.12, a P/E ratio of -7.13 and a beta of 3.14. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The business had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.07) EPS.
Several institutional investors have recently added to or reduced their stakes in ONCE. Ameritas Investment Partners Inc. raised its position in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Spark Therapeutics during the second quarter valued at approximately $143,000. BNP Paribas Arbitrage SA raised its position in shares of Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,449 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $225,000. Finally, Prudential Financial Inc. bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $239,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.
In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now owns 250,000 shares of the company’s stock, valued at $17,885,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Faga sold 6,000 shares of Spark Therapeutics stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $79.95, for a total transaction of $479,700.00. Following the transaction, the insider now directly owns 6,000 shares in the company, valued at approximately $479,700. The disclosure for this sale can be found here. Insiders have sold 62,309 shares of company stock worth $4,621,085 in the last ninety days. Insiders own 7.30% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.